Innovative Smartphone Application for Quitting Smoking among Seriously Mentally III

这个独立之路奖（PIA）的长期目标是开发一个研究计划，重点是使用移动的健康技术提高严重精神疾病（SMI）成年人戒烟干预的有效性和覆盖面。这一长期目标将通过一个为期5年的培训和研究计划来实现，该计划将启动Roger Vilardaga博士的独立研究和学术生涯计划。该奖项的职业目标是：（1）成为行为戒烟干预科学的专家;（2）掌握移动的健康干预措施的开发，测试和实施;（3）成为在SMI患者中实施临床试验的专家。这些职业目标将通过正式的课程，培训，研讨会，国家会议，导师和研究经验来实现。从本培训计划中获得的知识将使PI能够实现以下目标。在专家小组的指导下，第一个目标是开发一个接受和承诺疗法智能手机应用程序，用于SMI患者的戒烟，以及员工的智能手机指导指南。第二个目标是在10名患有SMI的人的样本中对最终的应用程序和指导指南进行迭代可用性测试。最后，第三个目标是进行一项双臂可行性随机试验，在来自社区环境的90名SMI患者样本中，将新应用程序与基于最佳实践戒烟指南（QuitGuide）的应用程序进行比较。两组均包括低成本药物干预（尼古丁替代治疗）。本试验的主要可行性结局（例如，招募率和保留率）将确定进行全把握度R 01试验的可靠方法学途径。Richard Ries博士将担任该PIA的主要导师，为Vilardaga博士接受培训并在新机构中成为独立调查员提供支持。SMI、戒烟、计算机科学和方法/统计学专家（Ries、McClernon、Ziedonis、Saxon、Kientz和阿特金斯博士）的指导和咨询团队将确保PI获得成功完成拟定研究所需的支持。K99将在华盛顿大学和西雅图的弗雷德哈钦森癌症研究中心举行。R 00将在杜克大学举行。这些尖端的研究机构将为完成PI的目标提供一个良好的环境。这项研究符合NIDA的主要计划优先事项，即使用创新技术并整合行为和药理干预措施，以改善物质使用治疗和结果（NOT-DA-10-019）。该研究解决了一个严重的问题-SMI患者的高吸烟率-它提出了在“现实世界”环境中使用更广泛的技术提供有希望的戒烟行为干预。该PIA将通过为SMI患者戒烟的移动的健康干预奠定职业基础，打造PI的独立之路。

The long term goal of this Pathway to Independence Award (PIA) is to develop a program of research focused on increasing the effectiveness and reach of smoking cessation interventions for adults with serious mental illness (SMI) using mobile health technology. This long term goal will be achieved via a 5-year training and research plan that will launch Dr. Roger Vilardaga’s independent program of research and academic career. The career objectives of this award are to: (1) become an expert in the science of behavioral smoking cessation interventions; (2) master the development, testing and implementation of mobile health interventions; (3) become an expert in the implementation of clinical trials in people with SMI. These career objectives will be achieved via formal coursework, trainings, seminars, national conferences, mentorship and research experience. The knowledge derived from this training plan will equip the PI to pursue the following aims. The first aim, guided by an expert panel, is to develop an Acceptance and Commitment Therapy smartphone application for smoking cessation for people with SMI, and a smartphone coaching guide for staff. The second aim is to conduct iterative usability testing of the resulting app and coaching guide in a sample of 10 people with SMI. Finally, the third aim is to conduct a two-arm feasibility randomized trial that compares the novel app to an app based on best-practice smoking cessation guidelines (QuitGuide) in a sample of 90 people with SMI from a community-based setting. Both arms will include a low cost pharmacological intervention (nicotine replacement therapy). The primary feasibility outcomes in this trial (e.g., recruitment and retention rates) will determine a reliable methodological approach to conduct a fully-powered R01 trial. Drs. Richard Ries will serve as the primary mentor on this PIA, providing support as Dr. Vilardaga receives his training and establishes himself as an independent investigator in a new institution. The mentoring and consulting team of experts in SMI, smoking cessation, computer science and methods/statistics (Drs. Ries, McClernon, Ziedonis, Saxon, Kientz and Atkins), will ensure that the PI receives the necessary support to successfully complete the proposed research. The K99 will take place at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle. The R00 will take place at Duke University. These cutting-edge research institutions will provide an excellent environment for completion of the PI’s objectives. This study meets NIDA’s major programmatic priorities of using innovative technologies and integrating behavioral and pharmacological interventions to improve substance use treatment and outcomes (NOT-DA-10-019). The study addresses a serious problem –high smoking rates in people with SMI–, and it proposes the delivery of a promising behavioral intervention for smoking cessation in a “real-world” setting using a wider reaching technology. This PIA will forge the PI’s pathway to independence by laying the foundation for a career in mobile health interventions for smoking cessation in people with SMI.